LYRA Live signals | Maximize Profits with Getagraph.com

BUY 102788 min ago

@ $4.78

Issued: 14 Feb 2024 @ 15:33

Return: 8.16%

Previous signal: Feb 9 - 14:49

Previous signal: Sell

Return: 2.36 %

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	105 297
Average Volume	345 850
Market Cap	308.87M
EPS	$0 ( 2024-04-03 )
Next earnings date	( $-0.260 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.10
ATR14	$0.00800 (0.15%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-18	Waksal Harlan	Buy	275 000	Common Stock
2024-03-18	Palasis Maria	Buy	500 000	Stock Option
2024-01-30	Bishop John E	Buy	200 000	Stock Options
2024-01-30	Nieman Richard	Buy	200 000	Stock Options
2024-01-30	Cavalier Jason	Buy	200 000	Stock Options

INSIDER POWER
100.00
Last 92 transactions
Buy: 35 062 945 \| Sell: 0

Volume Correlation

Long: -0.44 (neutral)

Short: 0.04 (neutral)

Signal:(28.471) Neutral

Lyra Therapeutics Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lyra Therapeutics Inc Correlation - Currency/Commodity

0.36
( neutral )

0.04
( neutral )

0.00
( neutral )

0.34
( neutral )

-0.38
( neutral )

-0.41
( neutral )

Lyra Therapeutics Inc Financials

Annual	2023
Revenue:	$1.56M
Gross Profit:	$1.28M (82.16 %)
EPS:	$-1.260

Q4	2023
Revenue:	$146 000
Gross Profit:	$61 000.00 (41.78 %)
EPS:	$-0.260

Q3	2023
Revenue:	$544 000
Gross Profit:	$-11.82M (-2 173.53 %)
EPS:	$-0.270

Q2	2023
Revenue:	$458 000
Gross Profit:	$-10.34M (-2 257.86 %)
EPS:	$-0.360

Financial Reports:

No articles found.

Lyra Therapeutics Inc

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.